Tinzaparin heparin (UFH or LMWH)

Description Results NMA

Symptomatic venous thromboembolism at the end of treatment 0.00 [0.00; NaN]

Symptomatic venous thromboembolism at the end of treatment 1.53 [0.26; 9.09]

Symptomatic venous thromboembolism at the end of treatment NaN [NaN; NaN]

Tinzaparin, 175 IU/kg once daily, 6 days (n=97)

vs.

Unfractioned heparin: bolus 5000 IU, infusion 29 760–40 320 IU/d (n=103)

sub group of patients with objectively documented PE in a trial enrolling patients with proximal-vein thrombosis

double blind

Parallel groups

Sample size: 97/103

Primary endpoint: none defined

FU duration: 3mo

Tinzaparin, 175 IU/kg once daily, 5 days (n=301)

vs.

Unfractioned heparin: bolus 50 IU/kg, infusion 500 IU/kg per day (n=307)

open

Parallel groups

Sample size: 301/307

Primary endpoint: recurrent thromboembolism, major bleeding, and death

FU duration: 3 mo

Tinzaparin, 175 IU/kg once daily, 5 days (n=6)

vs.

Unfractioned heparin: bolus 5000 IU, infusion 1400 IU/h (n=10)

open

Parallel groups

Sample size: 6/10

Primary endpoint:

FU duration: 3 mo

all cause death 0.00 [0.00; NaN]

total bleeding ∞ [NaN; ∞]

major Bleeding ∞ [NaN; ∞]

Pulmonary embolism 0.00 [0.00; NaN]

Asymptomatic Deep vein thrombosis 0.35 [0.10; 1.20]

wound hematoma NaN [NaN; NaN]

proximal deep vein thrombosis 0.00 [0.00; NaN]

PE NaN [NaN; NaN]

distal DVT 0.63 [0.30; 1.31]

VTE (symptomatic or asymptomatic) 0.59 [0.29; 1.23]

symptomatic VTE NaN [NaN; NaN]

Tinzaparin 3500 anti-Xa units (n=39)

vs.

Placebo (n=41)

Blind

Parallel groups

Sample size: 39/41

Primary endpoint:

FU duration:

Tinzaparin 3500 IU (n=99)

vs.

no prophylaxis (n=106)

open, assessor-blinded

Parallel groups

Sample size: 99/106

Primary endpoint:

FU duration: 38 days

tinzaparin 50/kg x1 +elastic stockings (n=105)

vs.

Placebo+elastic stockings (n=105)

double blind

Sample size: 105/105

Primary endpoint:

FU duration: 8-10 days

Tinzaparin 2500 and 3500 anti Xa units (n=861)

vs.

UFH 10 000 units (n=429)

Blind

Sample size: 861/429

Primary endpoint:

FU duration:

All-cause mortality 1.05 [0.60; 1.85]

Major hemorrhage 1.00 [0.36; 2.75]

Recurrent DVT/DVTextension (total) 0.44 [0.19; 1.02]

Thrombocytopenia 1.50 [0.44; 5.15]

death at 3 months 1.05 [0.60; 1.85]

Tinzaparin 175 antiXa/kg SQ daily for 12 weeks (n=-9)

vs.

UFH for 5 days followed by vitamin K antagonist (target INR 2-3) for 12 weeks (n=-9)

outcome assessment blinded

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 3 months

VTE during follow-up after active anticoagulant treatment 1.00 [0.50; 2.01]

VTE during active anticoagulant treatment 0.76 [0.40; 1.43]

DVT (recurrent) 0.21 [0.05; 0.92]

bleeding 0.34 [0.04; 3.24]

VTE at the end of trial 0.47 [0.19; 1.20]

VTE during follow-up after active anticoagulant treatment 0.17 [0.02; 1.40]

VTE during active anticoagulant treatment 0.73 [0.24; 2.24]

PE 1.37 [0.31; 5.98]

LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd (n=369)

vs.

UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 (n=368)

open

Sample size: 369/368

Primary endpoint:

FU duration: 9 mo

tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months (n=119)

vs.

acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) (n=122)

open

Parallel groups

Sample size: 119/122

Primary endpoint: symptomatic recurrent venous thromboembolism

FU duration: 12 months

Short term haemorrhage 0.09 [0.01; 0.72]

all cause death 0.49 [0.24; 1.02]

Recurrent thromboembolic event 0.41 [0.16; 1.04]

Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID (n=213)

vs.

unfractionated heparin intravenous APPTx2-3 (n=219)

Sample size: 213/219

Primary endpoint:

FU duration: 3 Months